Immuno-oncology Drugs and the Trouble with Market Access
Informa's Pink Sheet explores original research by Context Matters on market access challenges facing immuno-oncology drugs.
Note: Access to Pink Sheet requires a login and subscription.
Context Matters and IHS Markit Integration Featured in Pharmaceutical Commerce
Two drug-pricing firms combine data sets for a deeper picture on reimbursement decisions
Context Matters and IHS Markit provide analytics on pricing strategies
Pharmaceutical Commerce provides coverage on the new data integration collaboration between Context Matters and IHS Markit. The integration is driving the new combined pricing strategy tool PriceCurrents.
Context Matters Featured in pharmaphorum
Sovaldi and the Politics of High Priced Drugs: Are We Asking the Right Questions?
pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Associate Data Analyst Daniel Liden: "Sovaldi and the Politics of High Priced Drugs: Are We Asking the Right Questions?"
Overcoming the Market Access Hurdle through Better Planning of Clinical Trials
PharmaPhorum recently published an article written by our Founder and CEO Yin Ho and Associate Director of Data and Analytics Rachel Jao, "Overcoming the Market Access Hurdle through Better Planning of Clinical Trials." The article points out that though regulatory approval is still a key step in getting a drug to market, it no longer guarantees market access. The authors discuss how clinical-trial design and the implications on reimbursement can help companies make better use of their resources and expedite the path to a successful drug launch.
Picking Winners: Data Mining for Drug Discovery - CM Featured in Fierce Biotech
Fierce Biotech recently featured Context Matters in an e-book "Picking Winners: Data Mining for Drug Discovery". Our founder and CEO Yin Ho discusses how biotech and pharma companies are starting to understand the importance of reimbursement data and the insights that can be learned from following these patterns early in the drug development process.
Keeping the Fast Lane Open - DDN News Feature on Our FDA Breakthrough Designation Research
Drug Discovery News recently did a feature story, "Keeping the Fast Lane Open" that used our research and thinking from our three-part series "Life in the Fast Track." Since there has been a lot of discussion recently about the FDA’s new “Breakthrough Therapy” designation, we thought it would be interesting to look at some previous FDA fast lanes to see if they have actually made a difference in the speed and process of bringing drugs to market.
Pharmaceutical Trade Groups Endorse Data Sharing, with Conditions - Our CEO, Yin Ho, in Specialty Pharmacy Times
The trending topic of data transparency has been making news recently. The European Federation of Pharmaceutical Industries (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) have agreed to make their clinical trial data more readily available for public inquiry. Our Founder and CEO, Yin Ho, was asked to comment on this recently, in a Specialty Pharmacy Times piece, "Pharmaceutical Trade Groups Endorse Data Sharing, with Conditions."